Mechanisms Underlying the Differences in the Pharmacokinetics of Six Active Constituents of Huangqi Liuyi Decoction between Normal and Diabetic Nephropathy Mouse Models

Qun Wang,1 Yonglin Wang,2 Wen Liu,1 Dingyan Lu,2 Yang Jin,2 Nian Tang,1 Ya Shi,1 Zipeng Gong,2 Weiyi Tian,1 and Ting Liu2

1Guizhou University of Traditional Chinese Medicine, Huaxi University Town, Guiyang 550025, China
2Guizhou Provincial Key Laboratory of Pharmaceutics, Guizhou Medical University, Beijing Road, Guiyang 550004, China

Correspondence should be addressed to Zipeng Gong; gzp4012607@126.com, Weiyi Tian; tianweiyi@gzy.edu.cn, and Ting Liu; liitung@gmc.edu.cn

Received 13 May 2022; Revised 11 August 2022; Accepted 23 September 2022; Published 15 October 2022

Academic Editor: Dong Hyun Kim

Copyright © 2022 Qun Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The aim of this study was to explore the mechanisms underlying the differences in the pharmacokinetics of Huangqi Liuyi decoction extract (HQD) under physiological and pathological conditions. The roles of liver cytochrome P450 metabolic enzymes (Cyp450) and small intestinal transporters were also investigated. The cocktail probe drug method was used to investigate the effects of diabetic nephropathy (DN) and HQD on metabolic enzyme activity. The expression levels of liver Cyp450 metabolic enzymes (Cyp1A2, Cyp2C37, Cyp3A11, Cyp2E1, and Cyp2C11) and small intestinal transporters (breast cancer resistance protein (BCRP), P-glycoprotein (P-gp), organic cation transporters (OCTs), and multidrug resistance-associated protein (MRPs) were determined using western blot. Compared to normal mice, the expression of OCT1, OCT2, MRP1, and MRP2 was increased in DN mice, while that of P-gp and BCRP (P < 0.05 and P < 0.001) was inhibited. HQD inhibited expression of Cyp1A2 and Cyp3A11 and increased the expression of P-gp and BCRP in normal mice. In DN mice, HQD induced expression of BCRP and inhibited expression of Cyp2C37, Cyp3A11, OCT2, MRP1, and MRP2. The activity of each Cyp450 enzyme was consistent with changes in expression. The changes in pharmacokinetic parameters of HQD in DN might, in part, be secondary to decreased expression of P-gp and BCRP. HQD varied in regulating transporter activities between health and disease. These findings support careful application of HQD-based treatment in DN, especially in combination with other drugs.

1. Introduction

Diabetic nephropathy (DN), one of the most serious complications of diabetes mellitus, is characterized by proteinuria, microalbuminuria, increased blood pressure, and a continuous decline in the glomerular filtration rate [1–3]. Most cases progress to end-stage renal disease [4]. Prevention or early treatment of DN may improve patient survival and quality of life and lower medical costs [5]. Due to their limited side effects and toxicity, traditional Chinese medicines (TCMs) are widely applied in the treatment of diseases [6] including diabetic complications [7, 8]. Huangqi Liuyi decoction, which is composed of Radix Astragalus and Radix Glycyrrhiza, has been used in China since the Song dynasty. (A.D. 960 to 1279 A.D.). Astragalus inhibited the formation of renal interstitial fibrosis and slowed down the development of DN. Glycyrrhiza decreased fasting blood-glucose and antirenal oxidative stress [9, 10]. Huangqi Liuyi decoction significantly inhibited glucose reabsorption in renal tubular epithelial cells, decreasing the fasting blood glucose and limiting renal fibrosis in DN rats [11, 12]. In pilot studies [13], we found that several ingredients found in the Huangqi Liuyi decoction, namely, astragalus saponin, astragalus flavone, astragalus polysaccharide, and glycyrrhizic acid (AKA HQD), delayed the development of DN in db/db mice when combined. HQD could significantly
2. Materials and Methods

2.1. Materials. The following reference substances were employed: astragaloside IV (purity > 99.0%), calycosin-7-O-β-D-glucoside (purity > 98.0%), calycosin-glucuronide (purity > 98.0%), formononetin (purity > 98.0%), ononin (purity > 98.0%), and glycyrrhizic acid (purity > 99.0%). Puerarin (IS, purity > 98.0%) and digoxin (IS, purity > 98.0%) were obtained from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China).

Testosterone (D1509G72399) and acetaminophen (B14A9E58584) were obtained from Shanghai Yuanye Biotechnology Co., Ltd. (Shanghai, China); omeprazole (Y1306C4251), aglicem (Y08M8C0197), and chloroxazone (Y07MC714306) were obtained from Suzhou Meilun Biotechnology Co., Ltd. (Suzhou, China); dextorphan (JC0496-201606111) was obtained from Shanghai Jianchao Biotechnology Co., Ltd. (Shanghai, China); hydroxytestosterone (FN02261502) were obtained from A ChemTek Inc. (Worcester, MA, USA); and acetonitrile and methanol were purchased from Merck KGaA (Darmstadt, Germany). All other chemicals used were of analytical grade. The bicinchoninic acid (BCA) protein assay kit was obtained from Shanghai Solarbio Bioscience & Technology Co., Ltd. (Shanghai, China); the membrane protein extraction kit, goat antimouse immunoglobulin G (31430), and goat antirabbit (31460) were obtained from Thermo Fisher Scientific (Waltham, MA, USA); and anti-1A2 (ab178869), anti-2C9 (ab179808), anti-2C19 (ab22717), anti-BCRP (ab207732), anti-P-gp (ab170904), anti-MRP1 (ab32574), anti-MRP2 (ab203397), anti-OCT1 (ab203773), anti-OCT2 (ab22878), anti-OCT1A2 (ab2717), anti-OCT1B (ab2436), and anti-3A4 (ab3572) were obtained from Abcam (Cambridge, England).

We first determined the preparation process of astragalus saponins, astragalus flavones, astragalus polysaccharides, and glycyrrhizic acid extract. To this end, we prepared astragalus saponins and astragalus flavones extract using a macroporous resin column; astragalus polysaccharides extract was prepared using water extraction and alcohol precipitation; and glycyrrhizic acid extract was prepared using acetic precipitation. The extract content of each component extracted from the three batches of Astragalus and Glycyrrhiza is shown in Table 1.

According to the ratio of Huagqi Liuyide decoction (6:1, Astragalus: Glycyrrhiza), processing 18 kg of Astragalus and 3 kg of Glycyrrhiza yielded 115.38 g of astragalus saponins (72.04%, including 2.69% of astragaloside IV), 44.64 g of astragalus flavone (69.43%, including 1.62% of calycosin-7-O-β-D-glucoside, 1.42% of calycosin-glucuronide, 0.89% of ononin, 0.31% of formononetin), 279.36 g astragalus polysaccharides (65.82%), and 32.01 g glycyrrhizic acid (82.04%). The dry extract of astragalus saponins, astragalus flavones, astragalus polysaccharides, and glycyrrhizic acid was mixed together, and the HQD samples needed for this experiment were obtained. The high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) chromatogram of HQD is displayed in Figure 1. Puerarin and digoxin comprised the internal standard (IS). The HPLC-MS/MS chromatogram of the six reference substances (astragaloside IV, calycosin-7-O-β-D-glucoside, calycosin-glucuronide, ononin, formononetin, and glycyrrhizic acid) is shown in Figure 1(b), and the HQD sample is shown in Figure 1(c).

2.2. Animals. Ten-week-old db/db male mice and db/m mice were obtained from the Model Animal Research Center of Nanjing University (qualified number SCXK [Su] 2020–0018) and raised in a specific pathogen-free laboratory (SPF) of the Experimental Animal Center of Guizhou
Medical University for 2 weeks. Ten-week-old db/db mice develop nephropathy at 12 weeks of age [22, 23]. All mice were housed in polypropylene cages and maintained under standard conditions, with a relative humidity of 60% ± 5%, and a light-dark cycle of 12 h. Animal studies complied with the European Community guidelines (EEC
Directive of 1986; 86/609/EEC) and were approved by the Animal Ethical Committee of Guizhou Medical University (NO1702060).

2.3. Statistics. All data are presented as the mean ± standard deviation. Statistical analysis between the two groups was performed using the Statistical Package for the Social Sciences version 23 software program (IBM Corporation, Armonk, NY, USA). P-values < 0.05 between the two groups were considered statistically different.

2.4. Preparation of Mouse Liver Microsomes. The mice were sacrificed 24 hours after the last dose of HQD. Livers were quickly removed and then washed three times with ice-cold 1.15% KCl solution. They were then weighed and homogenized with a tissue grinder at 4,000 rpm in an ice-cold water bath. The resulting sediment was then suspended in phosphate-buffered saline (PBS, pH 7.4) and centrifuged at 12,000 × g for 20 minutes at 4°C. The supernatant fraction was centrifuged again at 100,000 × g for 45 minutes at 4°C. Then, the supernatant was discarded, and the liver microsomes were suspended uniformly with Tris-HCl buffer (pH 7.4). The protein concentration of the liver microsomes was determined using a BCA kit. Microsomes were stored at −80°C until use.

2.5. Effects of DN and HQD on the Activity of Liver Metabolic Enzymes. Liver metabolic enzymes, including CYP1A2, 2C19, 3A4, 2E1, and 2C9, were used as the research objects. The cocktail probe substrate method is the most commonly used method for the determination of metabolic enzyme activity [24]. The specific probe substrates of Cyp450 enzymes were incubated with the liver microsomes of the control group, model group, control HQD-3d group (normal mice were orally administered HQD 0.96 g/kg once a day for 3 consecutive days), and model HQD-3d group (model mice were orally administered HQD 0.96 g/kg once a day for 3 consecutive days). The cocktail probe substrate method (same oral administration as normal mice) was used to determine the metabolic enzyme activity in mice. The activity differences in major Cyp450 enzymes involved in drug metabolism among the different groups were evaluated by measuring the number of metabolites produced by specific probe substrates, and the effects of DN and HQD on Cyp450 enzyme activity in mice were characterized.

2.5.1. Preparation of Mixed Probe Substrate Solutions. Mixed probe substrate solutions were prepared separately by dissolving phenacetin, omeprazole, testosterone, chloroxazone, and tolbutamide into methanol. These solutions were diluted with PBS (1 mM; pH 7.0) to final concentrations of 150.0, 5.0, 2.5, 10.0, and 100.0 μmol/L before use, and then preheated at 37°C for standby.

2.5.2. Preparation of Mixed Probe Substrate Metabolite Solutions. Mixed probe substrate metabolite solutions were separately prepared by dissolving acetaminophen, 5-hydroxyomeprazole, 6β-hydroxytestosterone, 6-hydroxychloroxazone, 5-hydroxytolbutamide, and puerarin (IS) in methanol. These solutions were diluted with PBS (1 mM; pH 7.0) to final concentrations of 102.1, 102.9, 100.2, 100.5, 99.6 μg/mL, and 1 μg/mL before use, and then preheated at 37°C for standby.

2.5.3. Preparation of the Incubated Liver Microsome Samples in Vitro. The incubation system, with a total volume of 200 μL, consisted of liver microsomes (50 μL, 1 mg/mL), PBS (50 μL; pH 7.0), mixed probe substrate (80 μL total; with the concentrations of phenacetin, chloroxazone, omeprazole, tolbutamide, and testosterone being 100, 150, 25, 100, and 50 μmol/L, respectively), and NADPH (20 μL, 1 mM). All incubation samples were conducted in triplicate. The mixed solution of liver microsomes and probe substrate was preincubated at 37°C for 5 minutes. Then, NADPH, which was incubated at 37°C for 5 minutes, was added to initiate the reaction, and the incubation was allowed to continue at 37°C for 60 minutes in a constant temperature oscillator. To end the reaction, 400 μL of iced methanol containing the IS (puerarin, 1 μg/mL) was added. The samples were vortexed for 1 minute and centrifuged for 10 minutes (15,000 r/minute). HPLC-MS/MS was used to measure the metabolites of the probe substrates.

2.5.4. Conditions of Ultra-Performance Liquid Chromatography (UPLC)-MS/MS. The UPLC-MS/MS system consisted of an Acquity UPLC device (Waters Corporation, Milford, MA, USA) and a triple quadruple mass spectrometer (Triple Quad 5500; Applied Biosystems, Foster City, CA, USA) equipped with an electrospray ionization source. The Acquity Waters BEH C18 (2.1 × 50 mm, 1.7 μm) column was used. The mobile phases were as follows: water containing 0.1% formic acid and acetonitrile (mobile phase A) and 0.1% formic acid (mobile phase B). The gradient elution was as follows: 0 to 3 minutes (100% A), 3 to 3.5 minutes (65% A), and 3.5 to 4.5 minutes (90% A). The flow rate was 0.35 mL/minute, and the injection volume was 1 μL.

For MS/MS detection, an electrospray ionization in a multireaction monitoring mode was operated with polarity switching between negative and positive ion modes. The mass spectrometer parameters were set as follows: source temperature, 120°C; capillary voltage, 3 kV; drying gas flow rate (N2), 1000 L/h; gas temperature, 600°C; collision gas, Ar; flow rate (Ar), 0.16 mL/min. The MRM analysis was conducted by monitoring the precursor ion to produce ion transitions of m/z 152 → 110 for acetaminophen, 362.2 → 214 for 5-hydroxyomeprazole, 305.3 → 269.3 for 6β-hydroxytestosterone, 183.8 → 120 for 6-hydroxychloroxazone, 285 → 186 for 5-hydroxytolbutamide, and 417.1 → 267.1 for puerarin.

2.5.5. Changes in CYP450 Enzyme Activity in Different Groups of Mice. The corresponding mouse CYP450 enzymes, CYP450 isoenzyme probe substrates, and metabolites
of probe substrates are shown in Table 2 [25–29]. The liver microsomes of the control, model, control HQD-3d, and model HQD-3d groups were incubated with mixed probe substrates. Three parallel samples were set up in each group, and the production of the metabolites of probe substrates in each group was determined.

Table 2: Substrates and metabolites of CYP450 enzymes.

| Human liver CYP450 enzyme | Corresponding mouse CYP450 enzymes | Probe substrates | Metabolites                  |
|---------------------------|-----------------------------------|-----------------|------------------------------|
| CYP1A2                    | Cyp1A2                            | Phenacetin      | Acetaminophen                |
| CYP2C19                   | Cyp2C37                           | Omeprazole      | 5-hydroxyomeprazole          |
| CYP3A4                    | Cyp3A11                           | Testosterone    | 6β-hydroxytestosterone       |
| CYP2E1                    | Cyp2E1                            | Chlorzoxazone   | 6β-hydroxychlorozoxazone     |
| CYP2C9                    | CypC11                            | Tolbutamide     | 5-hydroxytobutamide          |

3. Results

3.1. Effects of DN and HQD on the Activity of Liver Metabolic Enzymes. Compared to the control group, the activity of Cyp2C11 and Cyp3A11 in the model group and Cyp2C11 in the control HQD-3d group was increased (Figure 2). The activities of Cyp1A2, Cyp2E1, Cyp3A11, and Cyp2C37 in the control HQD-3d group were decreased. Compared to the model group, the activities of Cyp1A2, Cyp3A11, and Cyp2C37 in the model HQD-3d group were decreased, while those of Cyp2C11 and Cyp2E1 were increased. DN induced the activity of Cyp2C11 and Cyp3A11. HQD inhibited the activity of Cyp1A2, Cyp2C37, Cyp3A11, and induced the activity of Cyp2C11. However, HQD inhibited the activity of Cyp2E1 in the control group, and induced the activity of Cyp2E1 in the model group. The results are shown in Figure 2 and Table 3.

3.2. Effects of DN and HQD on the Expression of Liver Metabolic Enzymes and Small Intestine Transporters

3.2.1. Effect of DN on the Expression of Liver Cyp450 Enzymes and Small Intestinal Transporters. The effects of DN on the expression of liver Cyp450 enzymes and small intestinal transporters are summarized in Table 3. Compared to normal mice, expression of Cyp1A2 and Cyp2E1 in DN mice was decreased, and the expression of Cyp2C11 and Cyp2C37 was increased, but there was no significant difference (Figure 3). The activity of each Cyp450 enzyme was consistent with the expression results. Compared to normal mice, the expression of P-gp and BCRP in DN mice was significantly lower, whereas the expression of OCT1, OCT2, MRP1, and MRP2 was significantly increased (P < 0.001) (Figure 4). The results showed that the functions of Cyp450 enzymes and transporters changed in the state of DN. DN induced the expression of Cyp2C11, Cyp2C37, OCT1, OCT2, MRP1, and MRP2, and inhibited the expression of Cyp1A2, Cyp2E1, P-gp, and BCRP.

3.2.2. Effects of HQD on the Expression of Liver Cyp450 Enzymes and Small Intestinal Transporters. The effects of HQD on the expression of liver Cyp450 enzymes and small intestinal transporters are shown in Table 3. Relevant western blots are also shown in Figure 3. As the clinical therapy requires long-term oral administration, in this experiment, animals were given multiple oral doses of the therapy. After 3 days of continuous administration, the effects of HQD on the expression of Cyp450 enzymes and intestinal transporters in normal and model mice were investigated. Compared to the control group, the expression of Cyp1A2 and Cyp3A11 in the control HQD-3d group was decreased significantly, and the expression of Cyp2E1 and Cyp2C37 tended to decrease, but there was no significant difference. Compared to the model group, the expression of Cyp2C37 and Cyp3A11 in the model HQD-3d group was decreased significantly, and while the expression of Cyp2E1 tended to increase, there was no significant difference. The activity of each Cyp450 enzyme was consistent with the expression result. Oral administration of HQD resulted in decreased expression of Cyp2C37 and Cyp3A11 in DN mice and decreased expression of Cyp1A2 and Cyp3A11 in normal mice.
The relevant western blots of small intestinal transporters are shown in Figure 4. Compared to the control group, the expression of intestinal transporters BCRP and P-gp in the control HQD-3d group was increased significantly, but the expression of OCT1, OCT2, MRP1, and MRP2 were unchanged. Compared to the model group, the expression of BCRP in the model HQD-3d group was increased significantly, while the expression of OCT2, MRP1, and MRP2 was decreased, and OCT1 and P-gp were unchanged. These results suggest that HQD stimulates the expression of BCRP and P-gp in normal mice, and BCRP in DN mice. Conversely, HQD inhibits the expression of OCT2, MRP1, and MRP2 in DN mice. The regulatory effects of HQD on some liver metabolic enzymes and transporters under physiological and pathological conditions are different.

4. Discussion

Liver CYP450s enzymes are involved in the metabolism of approximately 90% of clinical drugs [30], including CYP1,
CYP2, and CYP3. Among them, 1A2, 2C19, 3A4, 2E1, 2C9, and 2D6 are the six main subtypes of CYP450, accounting for approximately 80% of the total CYP450 enzymes in the liver [31]. In pilot studies, we found that the main active ingredients of HQD (astragaloside IV, calycosin-glucuronide, formononetin, and glycyrrhizic acid) may be metabolized by Cyp1A2, 2C19, 3A4, 2E1, and 2C9 (data unpublished). Therefore, 1A2, 2C19, 3A4, 2E1, and 2C9 were chosen for this study. Although CYP450 subtypes are species and genera-specific, they also have lineal homology and similar functions. Mouse Cyp1A2, 2C37, 3A11, 2E1, and 2C11 are homologous to human CYP1A2, 2C19, 3A4, 2E1, and 2C9, respectively [28, 29].

In the small intestine, transporters modulate the efflux and influx of exogenous and endogenous substances. Through controlling the cell transit of orally ingested substances, the transport enzyme system mediates drug disposition. Table 3: Changes in CYP450s and transporter enzymes after oral administration of HQD.

| No. | CYP450s and transporter | Model vs. Control | Control HQD-3d | Model HQD-3d vs. Model |
|-----|-------------------------|------------------|---------------|------------------------|
|     |                         | Activity         | Expression | Activity | Expression | Activity | Expression |
| 1   | Cyp1A2                  | ↓                | ↓           | ↓**      | ↑            | ↓        | ↓          |
| 2   | Cyp2C11                 | ↑***             | ↑           | ↑        | ↑             | ↑        | ↑          |
| 3   | Cyp2C37                 | ↑                | ↑           | ↓**      | ↓             | ↓        | ↓          |
| 4   | Cyp2E1                  | ↓                | ↓           | ↓        | ↓             | ↓        | ↓          |
| 5   | Cyp3A11                 | ↑***             | ↓           | ↓        | ↑***          | ↑        | ↑          |
| 6   | BCRP                    | —                | —           | —        | —             | —        | —          |
| 7   | P-gp                    | —                | —           | —        | —             | —        | —          |
| 8   | OCT1                    | —                | —           | —        | —             | —        | —          |
| 9   | OCT2                    | —                | —           | —        | —             | —        | —          |
| 10  | MRP1                    | —                | —           | —        | —             | —        | —          |
| 11  | MRP2                    | —                | —           | —        | —             | —        | —          |

* P < 0.05, ** P < 0.01, *** P < 0.001 compared to the control; # P < 0.05, ## P < 0.01, ### P < 0.001 compared to the model; no obvious trend “—”.

Figure 3: Protein expression of CYP450 metabolic enzymes (Cyp1A2, Cyp2C37, Cyp3A11, Cyp2E1, and Cyp2C11) in different groups (n = 3). * P < 0.05, ** P < 0.01, *** P < 0.001 compared to the control group; # P < 0.05, ## P < 0.01, ### P < 0.001 compared to the model group.

Figure 4: Protein expression of small intestinal transporters (BCRP, P-gp, OCT1, OCT2, MRP1, and MRP2) in different groups (n = 3). * P < 0.05, ** P < 0.01, *** P < 0.001 compared to the control group; # P < 0.05, ## P < 0.01, ### P < 0.001 compared to the model group.
bioavailability [32]. Of clinical relevance, the function and expression of drug transporters are altered in disease, which affect the treatment effects and pharmacokinetics. Clarifying the transport mechanism could improve the safety and effectiveness of drugs and improve clinical usage. Intestinal efflux transporters (e.g., P-gp, BCRP, and MRP) can have varied activities depending on the local balance between drug effect and overlap with other agents [33, 34]. Previous studies showed that the efflux of flavonoids and glucuronic acid metabolites contributes to their low bioavailability. In the intestine, flavonoids and glucuronide metabolites are excreted into the intestinal lumen by efflux transporters (i.e., P-gp, BCRP, and MRP2). For example, calycosin-7-O-β-D-glucoside is hydrolyzed into aglycon by hydrolase in the intestine. The generated metabolites can then be transported into the intestinal lumen by efflux transporters (BCRP or MRP2) [35].

When any drug is administered alone, the presence of chronic disease such as diabetes and subsequent DN is predicted to dominate drug availability. Changes in the expression levels of P-gp, BCRP, and MRP2 cause changes in the pharmacokinetic process of calycosin-7-O-β-D-glucoside, ononin, and the metabolites of aglycones. Glycyrrhizic acid can affect the function of P-gp on Caco-2 in the cell membrane, regulate P-gp-mediated drug efflux, and alter P-gp-mediated efflux, thus changing drug pharmacokinetics [36, 37]. Data indicated that P-gp inhibitors increased the efficacy and bioavailability of astragaloside IV, suggesting that astragaloside IV is a substrate of P-gp [38]. Changes in the expression levels of P-gp may account for altered in vivo pharmacokinetics of astragaloside IV and glycyrrhizic acid. Moreover, owing to the limited studies on OCTs, whether the up-regulation of OCT1 and OCT2 expression in DN is a factor in pharmacokinetic changes needs to be confirmed by further research.

In a single dose, we mainly consider the influence of pathological factors on drugs. Compared to normal mice, the expression of P-gp and BCRP in DN mice was significantly lower (P < 0.05 and P < 0.001); the activity and expression of Cyp2C11, Cyp3A11, and Cyp2C37 in DN mice was increased, while that of Cyp1A2 and Cyp2E1 was decreased. Drugs absorbed and excreted through the small intestine can also be metabolized by Cyp450s in the liver. The dual mediating effect of Cyp450s and the intestinal efflux transporter determines the speed and degree of drug absorption. Compared to the effect of Cyp2C11, Cyp3A11, and Cyp2C37, we speculate that the changes in pharmacokinetic parameters of HQD in DN may be mainly mediated by the down-regulation of P-gp and BCRP expression, which results in an increase in the AUC and a decrease in the Cl/Z/F of astragaloside IV, glycyrrhizic acid, calycosin-7-O-β-D-glucoside, ononin, and the metabolites of aglycones.

TCMs may inhibit or induce the expression of small intestine transporters, thus affecting the in vivo disposal of substrates. The results of the present study found that HQD increased expression of BCRP in normal and DN mice, increased expression of P-gp in normal mice, and inhibited expression of OCT2, MRP1, and MRP2 in DN mice. Therefore, the actions of HQD upon transporter expression levels were dependent upon the health status of the animals.

HQD inhibits the activity of Cyp1A2, Cyp2C37, and Cyp3A11, and induces the activity of Cyp2C11 in diabetic mice. Of relevance, many diabetes drugs are metabolized by CYP2C9, CYP3A4, and CYP2C8 [39]. For example, sulfonylurea hypoglycemics are metabolized by CYP2C9 and CYP3A4. Inhibition or induction of these enzymes will alter drug metabolism and likely increase plasma concentrations, which in turn may disturb the glucose balance [40, 41]. Together, our data underscore the need to employ HQD with caution in diabetic individuals, especially in the presence of chronic renal disease.

CYP450 enzymes participate in the synthesis and metabolism of bile and fatty acids and steroids. Changes in liver CYP450 enzymes and intestinal transporters have been noted in diabetes [42, 43]. In diabetics, testosterone, estradiol, and retinoic acid levels are decreased [44–47], suggesting a possible need for supplementation of testosterone, estradiol, and retinoic acid. Of note, testosterone, estradiol, and retinoic acid are metabolized by CYP3A4 [48]. We found that Cyp3A11 activity was increased in the model group but was decreased after HQD treatment. Mouse Cyp3A11 is homologous to human CYP3A4, and its function is similar [31]. It is thus expected that HQD will, via inhibition of CYP3A4, reduce elimination of testosterone, estradiol, and retinoic acid.

5. Conclusion
HQD altered protein levels and activity of multiple liver enzymes and intestinal epithelial transport molecules in a disease-dependent manner. Further, in animal DN, changes in HQD pharmacokinetics were linked to decreased expression of P-gp and BCRP. These data provide additional insights into the safe usage of HQD in health and DN. However, whether the six active ingredients (astragaloside IV, calycosin-7-O-β-D-glucoside, calycosin-glucuronide, ononin, formononetin, and glycyrrhizic acid) of HQD are transport substrates for P-gp and BCRP needs to be confirmed by further research.

Data Availability
The data used to support the findings of this study are available from the corresponding author upon reasonable request.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Authors’ Contributions
Qun Wang performed research design, conducted experiments, performed data analysis, and contributed to the writing of the manuscript. Wen Liu, Yang Jin, Yonglin Wang, Dingyan Lu, Nian Tang, and Ya Shi conducted experiments. Zipeng Gong performed research design and contributed to critical review of the paper. Weiyi Tian
conducted experiments, research design, and performed data analysis. Ting Liu conducted experiments, research design, and performed data analysis.

Acknowledgments

This research was supported by the Project of Guizhou Provincial Department of Education (No. KY[2021]033, QJHKYZ (2022) 257)), the Excellent Young Talents Plan of Guizhou Medical University (No. 2022-104), the Provincial Program on Scientific Research Projects of the Science and Technology Department of Guizhou Province (ID 7602992, 13 pages, 2022), and the National Training Program of Innovation and Entrepreneurship for Undergraduates (No. JGSH[2017]40), Guizhou University of Traditional Chinese Medicine Doctoral Starting Fund (ID 7602992, 13 pages, 2022).

References

[1] Z. H. Zhang, J. R. Mao, H. Chen et al., “Removal of uremic retention products by hemodialysis is coupled with indiscriminate loss of vital metabolites,” Clinical Biochemistry, vol. 50, no. 18, pp. 1078–1086, 2017.
[2] X. Y. Xiao, B. Ma, B. J. Dong et al., “Cellular and humoral immune responses in the early stages of diabetic nephropathy in NOD mice,” Journal of Autoimmunity, vol. 32, no. 2, pp. 85–93, 2009.
[3] J. Kopel, C. Pena-Hernandez, and K. Nugent, “Evolving spectrum of diabetic nephropathy,” World Journal of Diabetes, vol. 10, no. 5, pp. 269–279, 2019.
[4] H. Chen, L. Chen, D. Liu et al., “Combined clinical phenotype and lipidomic analysis reveals the impact of chronic kidney disease on lipid metabolism,” Journal of Proteome Research, vol. 16, no. 4, pp. 1566–1578, 2017.
[5] R. Correa-Rotter and L. Gonzalez-Michaca, “Early detection and prevention of diabetic nephropathy: a challenge calling for mandatory action for Mexico and the developing world,” Kidney International, vol. 68, no. 198, pp. S69–S75, 2005.
[6] Y. b. Peng, D. D. Ren, Y. F. Song et al., “Effects of a combined fucoidan and traditional Chinese medicine formula on hyperglycaemia and diabetic nephropathy in a type II diabetes mellitus rat model,” International Journal of Biological Macromolecules, vol. 147, pp. 408–419, 2020.
[7] X. Shi, X. G. Lu, L. B. Zhan et al., “The effects of the Chinese medicine ZiBu PiYin recipe on the hippocampus in a rat model of diabetes-associated cognitive decline: a proteomic analysis,” Diabetologia, vol. 54, no. 7, pp. 1888–1899, 2011.
[8] G. D. Sun, C. Y. Li, W. P. Cui et al., “Review of herbal traditional Chinese medicine for the treatment of diabetic nephropathy,” Journal of Diabetes Research, vol. 201618 pages, Article ID 5749857, 2016.
[9] K. K. Ma, Y. H. Ju, Q. Q. Chen, W. Z. Li, and W. P. Li, “Effect of astragaloside IV on regulation of P13K/Akt/FoxO1 signal in kidney of type 2 diabetic nephropathy rats,” Chinese Journal of Experimental Traditional Medical Formulae, vol. 2, no. 25, pp. 74–81, 2019.
[10] X. Lu and M. G. Wei, “Effects of astragalus polysaccharides on renal interstitial fibrosis in rats,” China Journal of Traditional Chinese Medicine and pharmacy, vol. 6, no. 29, pp. 1998–2001, 2014.
[11] Y. L. Xv, Y. J. Zhen, Z. Li, L. M. Wen, and W. F. Guo, “Effect of Huangqi liuyi tang on glucose re-absorption via renal tubular epithelial cells in type 2 diabetes model rats,” Chinese Journal of Experimental Traditional Medical Formulae, vol. 11, no. 23, pp. 114–121, 2017.
[12] L. M. Wen, Y. L. Xu, Z. Li, Y. J. Zhen, and W. F. Guo, “Study on the effects and mechanism of astragalus liuyi decoction on type 2 diabetes mellitus rats,” Journal of Chinese Medicinal Materials, vol. 41, no. 3, pp. 699–702, 2018.
[13] Q. Wang, Y. Shi, X. D. Liu et al., “Pharmacokinetic difference of six active constituents of Huangqi Liuyi decoction between control and diabetic nephropathy mouse models,” International Journal of Analytical Chemistry, vol. 2022, Article ID 7602992, 13 pages, 2022.
[14] R. C. Dong and Q. Meng, “Transporter-mediated interactions between traditional Chinese medicine and drugs,” World Science and Technology/Modernization of Traditional Chinese Medicine and Materia Medica, vol. 21, no. 2, pp. 216–219, 2019.
[15] Y. Z. Wang, X. X. Uo, and Y. Zheng, “Recent advances in intestinal "drug-metabolizing enzyme-efflux transporter coupling" and effect on bioavail-ability of flavonoids,” Chinese Journal of Hospital Pharmacy, vol. 39, no. 20, pp. 2107–2111, 2019.
[16] M. C. Joseph, M. D. Kirsteen, and J. H. Hazell, “An in vitro and in vivo evaluation of the effect of relacorilant on the activity of cytochrome P450 drug metabolizing enzymes,” The Journal of Clinical Pharmacology, vol. 61, no. 8, pp. 1–12, 2020.
[17] U. M. Zanger and M. Schwab, “Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation,” Pharmacology & Therapeutics, vol. 138, no. 1, pp. 103–141, 2013.
[18] F. Cao, Y. Gao, M. Wang, L. Fang, and Q. N. Ping, “Propylene glycol-linked amino acid/dipeptide diester produgs of oleic acid for pepT1-mediated transport: synthesis, intestinal permeability, and pharmacokinetics,” Molecular Pharmaceutics, vol. 10, no. 4, pp. 1378–1387, 2013.
[19] Y. Dong, Q. Yang, and X. X. Zhu, “Drug transporters of intestinal absorption,” Chinese Journal of Natural Medicines, vol. 6, no. 3, pp. 161–167, 2008.
[20] S. J. Shi, “Recent advances in intestinal "drug-metabolizing enzyme-efflux transporter coupling" and effect on bioavail-ability of flavonoids,” Chinese Journal of Hospital Pharmacy, vol. 39, no. 20, pp. 2107–2112, 2019.
[21] R. Silva, V. Vilas-Boas, H. Carmo et al., “Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy,” Pharmacology & Therapeutics, vol. 149, pp. 1–123, 2015.
[22] G. Appel, "Detecting and controlling diabetic nephropathy: what do we know," Cleveland Clinic Journal of Medicine, vol. 80, no. 4, pp. 209–217, 2013.
[23] C. Ponchiardi, M. Mauer, and B. Najafian, “Temporal profile of diabetic nephropathy pathologic changes,” Current Diabetes Reports, vol. 13, no. 4, pp. 592–599, 2013.
[24] B. Gawrońska-Szklarz, D. H. Musiał, A. Pawlik, and B. Najafian, “Temporal profile of diabetic nephropathy pathologic changes,” Current Diabetes Reports, vol. 13, no. 4, pp. 592–599, 2013.
hepatic cytochrome P450 enzymes by cocktail probe drugs,” *Journal of Ethnopharmacology*, vol. 139, no. 1, pp. 104–109, 2012.

[28] M. M. Li and T. Zhou, “Comparisons of cytochrome P450 orthologous subtypes in human, rat and mouse,” *Pharmaceutical Care and Research*, vol. 17, no. 2, pp. 81–86, 2017.

[29] M. Martignoni, G. M. M. Groothuis, and R. de Kanter, “Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction,” *Expert Opinion on Drug Metabolism and Toxicology*, vol. 2, no. 6, pp. 875–894, 2006.

[30] S. Rendić and F. Peter Guengerich, “Summary of information on the effects of ionizing and non-ionizing radiation on cytochrome P450 and other drug metabolizing enzymes and transporters,” *Current Drug Metabolism*, vol. 13, no. 6, pp. 847–852, 2012.

[31] J. Hou, E. Sun, J. Song et al., “Relationship between hepatic drug-metabolizing enzymes CYP450 and other drug metabolizing enzymes and transporters,” *Current Drug Metabolism*, vol. 13, no. 6, pp. 787–814, 2012.

[32] J. Shi, *Pharmacokinetics and Enterohepatic Disposition of Flavonoids of Astragali Radix*, Guangzhou University of Chinese Medicine, Guangzhou, China, 2013.

[33] D. He, Y. Miao, D. Q. Li, F. Q. Liu, and D. H. Xv, “Effects of radix glycyrrhiza and its main components on the function and expression of P-glycoprotein in Caco-2 Cells,” *Chinese Pharmaceutical Journal*, vol. 5, no. 45, pp. 752–755, 2010.

[34] H. Liu, L. T. Chen, F. Hui, L. Q. Di, and B. C. Cai, “Research and thinking on characteristics and mechanisms of absorption and metabolism of glycyrrhiza radix et rhizoma and its compatible interactions with other herbs,” *Chinese Traditional and Herbal Drugs*, vol. 43, no. 7, pp. 1443–1447, 2012.

[35] B. K. Thomson, T. D. Nolin, T. J. Velenosi et al., “Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms,” *American Journal of Kidney Diseases*, vol. 65, no. 4, pp. 574–582, 2015.

[36] Y. H. Lin, M. He, X. Q. Zhao, B. Q. Wang, and H. Wu, “Research progress of potential drug interactions of sulfonlyureas,” *Chinese Journal of Hospital Pharmacy*, vol. 8, no. 12, pp. 1333–1337, 2018.

[37] Z. Lin, S. B. Naraharisetty, L. Liu, H. G. Wang, and Q. C. Mao, “Contributions of human cytochrome P450 enzymes to glyburide metabolism,” *Biopharmaceutics & Drug Disposition*, vol. 5, no. 1, pp. 151–165, 2019.

[38] M. Y. Hu, C. Liu, M. Zhang, L. Hu, and X. D. Liu, “Alteration of cytochrome P450s activity under diabetic conditions and its impact on the development of diabetes mellitus,” *Journal of China Pharmaceutical University*, vol. 45, no. 2, pp. 153–160, 2014.

[39] P. Anzenbacher and E. Anzenbacherova, “Cytochromes P450 and metabolism of xenobiotics,” *Cellular and Molecular Life Sciences*, vol. 58, no. 5, pp. 737–747, 2001.